Second generation 2-pyridyl biphenyl amide inhibitors of the hedgehog pathway
摘要:
Potent and efficacious inhibitors of the hedgehog pathway for the treatment of cancer have been prepared using the 2-pyridyl biphenyl amide scaffold common to the clinical lead GDC-0449. Analogs with polar groups in the para-position of the aryl amide ring optimized potency, had minimal CYP inhibition, and possessed good exposure in rats. Compounds 9d and 14f potently inhibited hedgehog signaling as measured by Gli1 mRNA and were found to be equivalent or more potent than GDC-0449, respectively, when studied in a Ptch(+/) medulloblastoma allograft model, that is, highly dependent on hedgehog signaling. (C) 2010 Elsevier Ltd. All rights reserved.
The invention provides novel inhibitors of hedgehog signaling that are useful as a therapeutic agents for treating malignancies where the compounds have the general formula I:
wherein A, X, Y R
1
, R
2
, R
3
, R
4
, m and n are as described herein.
[EN] PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING<br/>[FR] INHIBITEURS PYRIDYLES DE LA SIGNALISATION HEDGEHOG
申请人:GENENTECH INC
公开号:WO2006028958A2
公开(公告)日:2006-03-16
The invention provides novel inhibitors of hedgehog signaling that are useful as a therapeutic agents for treating malignancies where the compounds have the general formula I: wherein A, X, Y, R1, R2, R3, R4, and n are as described herein.